After India: Daiichi Sankyo has to close a research and development base in Japan
Daiichi Sankyo Co., Ltd. announced today that it will close Asubio Pharma, a research subsidiary in Kobe, Japan. The move is mainly due to the restructuring of its global R&D deployment, which is expected to close by the end of March 2018. Just one month before the announcement of the news, the company announced that it is closing its research and development base in Gurgaon, India. At the time, the company stated that “the first three are reviewing its global R&D system, with the aim of reducing R&D operation costs, reconfiguring resources, and pushing the R&D line further.†Closing the Indian factory will affect approximately 170 employees. The first three took over the Gurgaon Center in 2008 when it acquired the R&D department of Ranbaxy (BOBAXY.BO). At the time, the R&D base had about 200 scientists. The acquisition amount is 4 billion US dollars. In 2014, four major factories in the first three countries were shut down by the United States for fine data and production management, and were fined $500 million. Later, they sold Ranbaxy to Sun Pharmaceuticals (SUNPHARMA.NS). Prior to this, the first three also closed the R&D base in the UK. In February 2016, the first three companies announced the closure of the plant in Gerrards Cross, England, which has 80 employees and whose operations were transferred to Edison, a subsidiary in New Jersey, and a subsidiary in Munich, Germany. Asubio Pharma employs approximately 150 people and is primarily involved in the development of mental and neurological diseases, immune and inflammatory diseases and regenerative medicine. After the reorganization, the first three hope to transfer Asubio's R&D operations and employees to its subsidiaries in Japan. The first three said in the statement, "We hope to integrate Asubio's entrepreneurial spirit into other research bases of the first three countries, greatly improving R&D efficiency." Endpoints News contributor John Carroll said, "Every major European and American pharmaceutical company in the US and Europe has carried out research and development restructuring, and sometimes even more than one reorganization in the past five years. The first three republics and Takeda (TKPYY) are also following this time. The torrent of the relocation has moved to global centers such as Boston, Cambridge and the Gulf." The first three have bases in Korea, China, Taiwan, and Munich, Germany. Desk Mini Fans,Portable Mini Fan,Mini Fan USB,Mini Fan Cooler,Handheld Mini fan Ningbo Shuangtuo International Trade Co., Ltd. , https://www.nbst-sports.com